The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease

Progress in Lipid Research

Volumn 47, Issue 2, 2008, Pages 107-126

  Hikiji, Hisako ^a   Takato, Tsuyoshi ^a   Shimizu, Takao ^a   Ishii, Satoshi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Japan Science and Technology Agency   (Japan)

Author keywords

Osteoblast; Osteoclast; Osteoporosis; PAF; PGE2

Indexed keywords

7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; [3 [[(4 TERT BUTYLBENZYL)(3 PYRIDINESULFONYL)AMINO]METHYL]PHENOXY]ACETIC ACID; APAFANT; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA;

BONE DISEASE; BONE METABOLISM; BONE REMODELING; DIARRHEA; EXTRACELLULAR MATRIX; FLUSHING; FRACTURE; HUMAN; LETHARGY; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PERIODONTITIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DISEASES; CELL DIFFERENTIATION; DOGS; EXTRACELLULAR MATRIX; FRACTURES, BONE; HUMANS; INTERLEUKINS; LEUKOTRIENES; MICE; OSTEOBLASTS; PEPTIDE HYDROLASES; PERIODONTITIS; PLATELET ACTIVATING FACTOR; PROSTAGLANDINS; RANK LIGAND; RATS; RECEPTORS, PROSTAGLANDIN E;

MUS;

EID: 39749173767     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2007.12.003     Document Type: Review

References (291)

1. 2s. Biochim Biophys Acta 1761 (2006) 1317-1322
2. 2 enzymes. Prostaglandins Other Lipid Mediat 68-69 (2002) 3-58
3. 2+-dependent translocation domain with homology to PKC and GAP. Cell 65 (1991) 1043-1051
4. Merlie J.P., Fagan D., Mudd J., and Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 263 (1988) 3550-3553
5. DeWitt D.L., and Smith W.L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85 (1988) 1412-1416
6. Yokoyama C., Takai T., and Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 231 (1988) 347-351
7. Fletcher B.S., Kujubu D.A., Perrin D.M., and Herschman H.R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 267 (1992) 4338-4344
8. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
9. Jakobsson P.J., Thoren S., Morgenstern R., and Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96 (1999) 7220-7225
10. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275 (2000) 32783-32792
11. 2 biosynthesis. J Biol Chem 275 (2000) 32775-32782
12. Tanikawa N., Ohmiya Y., Ohkubo H., Hashimoto K., Kangawa K., Kojima M., et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun 291 (2002) 884-889
13. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 (1999) 1193-1226
14. Matsumoto T., Funk C.D., Radmark O., Hoog J.O., Jornvall H., and Samuelsson B. Molecular cloning and amino acid sequence of human 5-lipoxygenase. Proc Natl Acad Sci USA 85 (1988) 26-30
15. Dixon R.A.F., Jones R.E., Diehl R.E., Bennett C.D., Kargman S., and Rouzer C.A. Cloning of the cDNA for human 5-lipoxygenase. Proc Natl Acad Sci USA 85 (1988) 416-420
16. Dixon R.A., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
17. 4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. Proc Natl Acad Sci USA 83 (1986) 4175-4179
18. 4 synthase activities. Proc Natl Acad Sci USA 83 (1986) 857-861
19. Powell W.S., and Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 44 (2005) 154-183
20. 4 hydrolase: complete primary structure of an enzyme involved in eicosanoid synthesis. J Biol Chem 262 (1987) 13873-13876
21. 4 hydrolase. Proc Natl Acad Sci USA 84 (1987) 6677-6681
22. 4. Proc Natl Acad Sci USA 91 (1994) 7663-7667
23. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
24. Snyder F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J 305 (1995) 689-705
25. Prescott S.M., Zimmerman G.A., Stafforini D.M., and McIntyre T.M. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69 (2000) 419-445
26. 2 in allergic response and parturition. Nature 390 (1997) 618-622
27. 2 and platelet-activating factor receptor in the Ca-induced biosynthesis of PAF. Biochem Biophys Res Commun 271 (2000) 812-817
28. Shindou H., Hishikawa D., Nakanishi H., Harayama T., Ishii S., Taguchi R., et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase. J Biol Chem 282 (2007) 6532-6539
29. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
30. Hla T., Lee M.J., Ancellin N., Paik J.H., and Kluk M.J. Lysophospholipids-receptor revelations. Science 294 (2001) 1875-1878
31. Watkins B.A., Li Y., and Seifert M.F. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. J Am Coll Nutr 20 (2001) 410S-416S discussion 17S-20S
32. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40 (2007) 1434-1446
33. Suda T., Ueno Y., Fujii K., and Shinki T. Vitamin D and bone. J Cell Biochem 88 (2003) 259-266
34. Woolf A.D. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 19 (2007) 370-375
35. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115 (2005) 3318-3325
36. Lieberman J.R., Daluiski A., and Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84-A (2002) 1032-1044
37. Kwan Tat S., Padrines M., Theoleyre S., Heymann D., and Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15 (2004) 49-60
38. Pilbeam C.C., Harrison J.R., and Raisz L.G. Prostaglandins and bone metabolism. In: Bilekizian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology. 2nd ed. (2002), Academic Press, San Diego 979-994
39. Klein D.C., and Raisz L.G. Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 86 (1970) 1436-1440
40. Hikiji H., Ishii S., Shindou H., Takato T., and Shimizu T. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy. J Clin Invest 114 (2004) 85-93
41. Raisz L.G., Pilbeam C.C., and Fall P.M. Prostaglandins: mechanisms of action and regulation of production in bone. Osteoporos Int 3 Suppl. 1 (1993) 136-140
42. Krieger N.S., Parker W.R., Alexander K.M., and Bushinsky D.A. Prostaglandins regulate acid-induced cell-mediated bone resorption. Am J Physiol Renal Physiol 279 (2000) F1077-F1082
43. Suzawa T., Miyaura C., Inada M., Maruyama T., Sugimoto Y., Ushikubi F., et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141 (2000) 1554-1559
44. 2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J Bone Miner Res 11 (1996) 62-71
45. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105 (2000) 823-832
46. 2 induction in neonatal mouse parietal bone cultures. J Bone Miner Res 11 (1996) 358-366
47. Onoe Y., Miyaura C., Kaminakayashiki T., Nagai Y., Noguchi K., Chen Q.R., et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156 (1996) 758-764
48. 2. Endocrinology 130 (1992) 443-448
49. 2 on mineralization of bone nodules formed by fetal rat calvarial cells. Calcif Tissue Int 55 (1994) 451-457
50. 2 promote osteoblast-like differentiation in MC3T3-E1 cells. Cell Death Differ 14 (2007) 1792-1801
51. Choudhary S., Kumar A., Kale R.K., Raisz L.G., and Pilbeam C.C. Extracellular calcium induces COX-2 in osteoblasts via a PKA pathway. Biochem Biophys Res Commun 322 (2004) 395-402
52. Choudhary S., Wadhwa S., Raisz L.G., Alander C., and Pilbeam C.C. Extracellular calcium is a potent inducer of cyclo-oxygenase-2 in murine osteoblasts through an ERK signaling pathway. J Bone Miner Res 18 (2003) 1813-1824
53. Knothe Tate M.L., Knothe U., and Niederer P. Experimental elucidation of mechanical load-induced fluid flow and its potential role in bone metabolism and functional adaptation. Am J Med Sci 316 (1998) 189-195
54. Mehrotra M., Saegusa M., Voznesensky O., and Pilbeam C. Role of Cbfa1/Runx2 in the fluid shear stress induction of COX-2 in osteoblasts. Biochem Biophys Res Commun 341 (2006) 1225-1230
55. Xiao G., Jiang D., Thomas P., Benson M.D., Guan K., Karsenty G., et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 275 (2000) 4453-4459
56. Franceschi R.T., and Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88 (2003) 446-454
57. Wadhwa S., Godwin S.L., Peterson D.R., Epstein M.A., Raisz L.G., and Pilbeam C.C. Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway. J Bone Miner Res 17 (2002) 266-274
58. Wadhwa S., Choudhary S., Voznesensky M., Epstein M., Raisz L., and Pilbeam C. Fluid flow induces COX-2 expression in MC3T3-E1 osteoblasts via a PKA signaling pathway. Biochem Biophys Res Commun 297 (2002) 46-51
59. 2 release in MC3T3-E1 osteoblasts. J Appl Physiol 97 (2004) 135-142
60. Forwood M.R. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11 (1996) 1688-1693
61. 2 increases the skeletal response to mechanical loading. J Bone Miner Res 12 (1997) 276-282
62. Suda M., Tanaka K., Natsui K., Usui T., Tanaka I., Fukushima M., et al. Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 137 (1996) 1698-1705
63. 2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 275 (2000) 19819-19823
64. 2 receptor subtypes in human bone tissue: differences in foetal, adult normal, osteoporotic and pagetic bone. Prostaglandins Leukot Essent Fatty Acids 70 (2004) 431-439
65. Narumiya S., and FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108 (2001) 25-30
66. 2 and selective prostaglandin receptor agonists in murine osteoblastic cells. Bone 34 (2004) 827-834
67. Sakuma Y., Tanaka K., Suda M., Yasoda A., Natsui K., Tanaka I., et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 15 (2000) 218-227
68. 2 stimulated hypercalcemia in mice in vivo. Prostaglandins Other Lipid Mediat 67 (2002) 173-180
69. 2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 30 (2002) 567-573
70. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141 (2000) 2054-2061
71. 2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat 81 (2006) 178-183
72. 1 subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells. Calcif Tissue Int 62 (1998) 327-331
73. 2 receptor. J Cell Biochem 75 (1999) 215-225
74. 1 receptor, phospholipase C, protein kinase Cα, and c-Src pathway in primary cultured rat osteoblasts. J Biol Chem 280 (2005) 22907-22916
75. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone 25 (1999) 517-523
76. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 (1998) 3597-3602
77. Fuller K., Wong B., Fox S., Choi Y., and Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188 (1998) 997-1001
78. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
79. 2 in human bone marrow stroma cells. Biochem Biophys Res Commun 247 (1998) 338-341
80. 2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J Immunol 172 (2004) 2504-2510
81. Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe E., Nakamura Y., et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145 (1990) 3297-3303
82. 3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 13 (1998) 393-399
83. 2: cross-talk regulation by protein kinase C. Bone 22 (1998) 355-360
84. 2 and calcemic hormones of IL-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun 270 (2000) 1080-1085
85. 2 in fetal rat osteoblasts: role of protein kinase A signaling pathway. J Bone Miner Res 13 (1998) 1092-1100
86. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58 (1989) 573-581
87. Udagawa N., Takahashi N., Katagiri T., Tamura T., Wada S., Findlay D.M., et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 182 (1995) 1461-1468
88. Palmqvist P., Persson E., Conaway H.H., and Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae. J Immunol 169 (2002) 3353-3362
89. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 148 (1992) 2175-2180
90. 2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system. Endocrinology 146 (2005) 1991-1998
91. Lorenzo J.A., Sousa S.L., Alander C., Raisz L.G., and Dinarello C.A. Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. Endocrinology 121 (1987) 1164-1170
92. Linkhart T.A., and MacCharles D.C. Interleukin-1 stimulates release of insulin-like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism. Endocrinology 131 (1992) 2297-2305
93. 2 stimulates osteoclast formation via endogenous IL-1β expressed through protein kinase A. J Immunol 156 (1996) 1931-1936
94. 2 induces IL-1β gene expression in mouse osteoblasts through a cAMP-PKA signaling pathway. Int Immunopharmacol 4 (2004) 779-789
95. Akatsu T., Takahashi N., Udagawa N., Imamura K., Yamaguchi A., Sato K., et al. Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J Bone Miner Res 6 (1991) 183-189
96. 2 production and decreasing OPG production by osteoblasts. Life Sci 77 (2005) 615-626
97. Jimi E., Ikebe T., Takahashi N., Hirata M., Suda T., and Koga T. Interleukin-1α activates an NF-κB-like factor in osteoclast-like cells. J Biol Chem 271 (1996) 4605-4608
98. Jimi E., Nakamura I., Ikebe T., Akiyama S., Takahashi N., and Suda T. Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273 (1998) 8799-8805
99. Pilbeam C.C., Raisz L.G., Voznesensky O., Alander C.B., Delman B.N., and Kawaguchi H. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. J Bone Miner Res 10 (1995) 406-414
100. 2. J Biol Chem 272 (1997) 19891-19897
101. Chambers T.J., Thomson B.M., and Fuller K. Effect of substrate composition on bone resorption by rabbit osteoclasts. J Cell Sci 70 (1984) 61-71
102. Sakamoto S., and Sakamoto M. Osteoblast collagenase: collagenase synthesis by clonally derived mouse osteogenic (MC3T3-E1) cells. Biochem Int 9 (1984) 51-58
103. Holliday L.S., Welgus H.G., Fliszar C.J., Veith G.M., Jeffrey J.J., and Gluck S.L. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 272 (1997) 22053-22058
104. 2 induces the gene expression of bone matrix metalloproteinase-1 in mouse osteoblasts by cAMP-PKA signaling pathway. Int J Biochem Cell Biol 37 (2005) 375-385
105. Blobel C.P. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNFα and Notch. Cell 90 (1997) 589-592
106. Miles R.R., Sluka J.P., Halladay D.L., Santerre R.F., Hale L.V., Bloem L., et al. ADAMTS-1: a cellular disintegrin and metalloprotease with thrombospondin motifs is a target for parathyroid hormone in bone. Endocrinology 141 (2000) 4533-4542
107. Komori T. Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab 21 (2003) 193-197
108. Yoshida K., Oida H., Kobayashi T., Maruyama T., Tanaka M., Katayama T., et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci USA 99 (2002) 4580-4585
109. Wozney J.M., and Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res (1998) 26-37
110. Ducy P., Zhang R., Geoffroy V., Ridall A.L., and Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 (1997) 747-754
111. 2 in human mesenchymal stem cells. J Cell Physiol 200 (2004) 400-406
112. Garcia A.J., and Reyes C.D. Bio-adhesive surfaces to promote osteoblast differentiation and bone formation. J Dent Res 84 (2005) 407-413
113. 2 stimulates collagen and non-collagen protein synthesis and prolyl hydroxylase activity in osteoblastic clone MC3T3-E1 cells. Biochem Biophys Res Commun 126 (1985) 340-345
114. Globus R.K., Doty S.B., Lull J.C., Holmuhamedov E., Humphries M.J., and Damsky C.H. Fibronectin is a survival factor for differentiated osteoblasts. J Cell Sci 111 (1998) 1385-1393
115. 2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene. J Biol Chem 278 (2003) 28659-28667
116. 2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140 (1999) 1927-1935
117. 2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 280 (2005) 24035-24042
118. 2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 280 (2005) 11395-11403
119. 2 strongly inhibits human osteoclast formation. Endocrinology 146 (2005) 5204-5214
120. 2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro. Endocrinology 139 (1998) 3157-3164
121. 2 inhibits formation of osteoclastlike cells in long-term human marrow cultures but is not a mediator of the inhibitory effects of transforming growth factor β. J Bone Miner Res 5 (1990) 677-681
122. 3 receptors on osteoclasts of calcium-deficient chicken despite demonstrable receptors on circulating monocytes. J Clin Invest 77 (1986) 312-314
123. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191 (2000) 275-286
124. 2 act directly on circulating human osteoclast precursors. Biochem Biophys Res Commun 264 (1999) 590-595
125. Suzuki H., Nakamura I., Takahashi N., Ikuhara T., Matsuzaki K., Isogai Y., et al. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 137 (1996) 4685-4690
126. 2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor. Calcif Tissue Int 67 (2000) 85-92
127. Sarrazin P., Hackett J.A., Fortier I., Gallant M.A., and de Brum-Fernandes A. Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts. J Rheumatol 31 (2004) 1598-1606
128. Li M., Healy D.R., Li Y., Simmons H.A., Crawford D.T., Ke H.Z., et al. Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. Bone 37 (2005) 46-54
129. Akhter M.P., Cullen D.M., and Pan L.C. Bone biomechanical properties in EP4 knockout mice. Calcif Tissue Int 78 (2006) 357-362
130. Akhter M.P., Cullen D.M., Gong G., and Recker R.R. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 29 (2001) 121-125
131. 2 and risedronate administration on cancellous bone in older female rats. Bone 15 (1994) 489-496
132. 2 on bone mass in rat long bones and calvariae. J Endocrinol 156 (1998) 51-57
133. 2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res 18 (2003) 2033-2042
134. Bostrom M.P. Expression of bone morphogenetic proteins in fracture healing. Clin Orthop Relat Res (1998) S116-S123
135. Dekel S., Lenthall G., and Francis M.J. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J Bone Joint Surg Br 63-B (1981) 185-189
136. Gerstenfeld L.C., Thiede M., Seibert K., Mielke C., Phippard D., Svagr B., et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 21 (2003) 670-675
137. Endo K., Sairyo K., Komatsubara S., Sasa T., Egawa H., Yonekura D., et al. Cyclooxygenase-2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 21 (2002) 235-238
138. Harder A.T., and An Y.H. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. J Clin Pharmacol 43 (2003) 807-815
139. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., and O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109 (2002) 1405-1415
140. 2 agonist induces bone healing. Proc Natl Acad Sci USA 100 (2003) 6736-6740
141. Nomura S., and Takano-Yamamoto T. Molecular events caused by mechanical stress in bone. Matrix Biol 19 (2000) 91-96
142. Stepan J.J., Pospichal J., Presl J., and Pacovsky V. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8 (1987) 279-284
143. 2 increased rat cortical bone mass when administered immediately following ovariectomy. Bone Miner 21 (1993) 189-201
144. 2 administration prevents bone loss induced by orchidectomy in rats. J Bone Miner Res 10 (1995) 66-73
145. 4 receptor subtype. Am J Physiol 276 (1999) E376-E383
146. 2 agonist restores bone mass and strength in aged, ovariectomized rats. J Bone Miner Res 21 (2006) 565-575
147. McClung M.R. The menopause and HRT. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 17 (2003) 53-71
148. Lane N., Coble T., and Kimmel D.B. Effect of naproxen on cancellous bone in ovariectomized rats. J Bone Miner Res 5 (1990) 1029-1035
149. 2 preserve bone architecture following ovariectomy in adult rats. Bone 39 (2006) 134-142
150. Bauer D.C., Orwoll E.S., Fox K.M., Vogt T.M., Lane N.E., Hochberg M.C., et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11 (1996) 29-35
151. Carbone L.D., Tylavsky F.A., Cauley J.A., Harris T.B., Lang T.F., Bauer D.C., et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18 (2003) 1795-1802
152. Morton D.J., Barrett-Connor E.L., and Schneider D.L. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J Bone Miner Res 13 (1998) 1924-1931
153. 2. J Endocrinol 158 (1998) R1-R5
154. Sato K., and Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 18 (2006) 419-426
155. Martel-Pelletier J., Pelletier J.P., and Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 33 (2003) 155-167
156. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103 (1999) 1345-1352
157. Kojima F., Naraba H., Sasaki Y., Okamoto R., Koshino T., and Kawai S. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J Rheumatol 29 (2002) 1836-1842
158. 2 biosynthetic pathway. Arthritis Rheum 52 (2005) 3439-3447
159. Luross J.A., and Williams N.A. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 103 (2001) 407-416
160. 2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203 (2006) 325-335
161. 2α-deficient mice are resistant to collagen-induced arthritis. J Exp Med 197 (2003) 1297-1302
162. Myers L.K., Kang A.H., Postlethwaite A.E., Rosloniec E.F., Morham S.G., Shlopov B.V., et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 43 (2000) 2687-2693
163. Trebino C.E., Stock J.L., Gibbons C.P., Naiman B.M., Wachtmann T.S., Umland J.P., et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100 (2003) 9044-9049
164. Kamei D., Yamakawa K., Takegoshi Y., Mikami-Nakanishi M., Nakatani Y., Oh-Ishi S., et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 279 (2004) 33684-33695
165. 2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110 (2002) 651-658
166. Ghosh P., and Smith M. Osteoarthritis, genetic and molecular mechanisms. Biogerontology 3 (2002) 85-88
167. Smith M.D., Triantafillou S., Parker A., Youssef P.P., and Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24 (1997) 365-371
168. 2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46 (2002) 1789-1803
169. 2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 136 (2002) 287-295
170. 2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. J Bone Miner Res 16 (2001) 713-721
171. Blanco F.J., Guitian R., Vazquez-Martul E., de Toro F.J., and Galdo F. Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 41 (1998) 284-289
172. 2 via the induction of cyclooxygenase-2. J Immunol 165 (2000) 3402-3410
173. Heitz-Mayfield L.J. Disease progression: identification of high-risk groups and individuals for periodontitis. J Clin Periodontol 32 Suppl. 6 (2005) 196-209
174. Rams T.E., Listgarten M.A., and Slots J. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis subgingival presence, species-specific serum immunoglobulin G antibody levels, and periodontitis disease recurrence. J Periodontal Res 41 (2006) 228-234
175. Wada N., Maeda H., Yoshimine Y., and Akamine A. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 35 (2004) 629-635
176. Yip K.H., Zheng M.H., Feng H.T., Steer J.H., Joyce D.A., and Xu J. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-κB activity. J Bone Miner Res 19 (2004) 1905-1916
177. 2 production. Bone 36 (2005) 267-275
178. 1α in experimentally induced periapical inflammatory lesions in rats. J Endod 22 (1996) 635-637
179. 4 in the gingival crevicular fluid. J Dent 26 (1998) 97-103
180. 2-mediated bone resorption associated with inflammation. J Exp Med 197 (2003) 1303-1310
181. 2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. J Immunol 177 (2006) 1879-1885
182. Sakuma Y., Tanaka K., Suda M., Komatsu Y., Yasoda A., Miura M., et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun 68 (2000) 6819-6825
183. Williams R.C., Jeffcoat M.K., Kaplan M.L., Goldhaber P., Johnson H.G., and Wechter W.J. Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. Science 227 (1985) 640-642
184. Williams R.C., Jeffcoat M.K., Howell T.H., Rolla A., Stubbs D., Teoh K.W., et al. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 60 (1989) 485-490
185. 2 enhances alveolar bone formation in the rat mandible. Bone 35 (2004) 1361-1368
186. 2 reduces trap, calcitonin receptor and metalloproteinase-2 immunoreactivity in the rat periodontium. Arch Oral Biol 50 (2005) 1014-1022
187. Feyen J.H., van der Wilt G., Moonen P., Di Bon A., and Nijweide P.J. Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drugs. Prostaglandins 28 (1984) 769-781
188. 2) in aqueous solutions. Prostaglandins 15 (1978) 943-954
189. Raisz L.G., Vanderhoek J.Y., Simmons H.A., Kream B.E., and Nicolaou K.C. Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin. Prostaglandins 17 (1979) 905-914
190. 2): a potential mediator of c-fos expression induced by hydrostatic pressure in osteoblastic cells. Eur J Clin Invest 26 (1996) 544-548
191. Turner C.H., Forwood M.R., Rho J.Y., and Yoshikawa T. Mechanical loading thresholds for lamellar and woven bone formation. J Bone Miner Res 9 (1994) 87-97
192. Joldersma M., Burger E.H., Semeins C.M., and Klein-Nulend J. Mechanical stress induces COX-2 mRNA expression in bone cells from elderly women. J Biomech 33 (2000) 53-61
193. 2 and dibutyryl cyclic AMP on the cytoplasmic spreading of rat osteoclasts. Br J Exp Pathol 65 (1984) 557-566
194. γ and β/δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids. Calcif Tissue Int 76 (2005) 385-392
195. Brodie M.J., Hensby C.N., Parke A., and Gordon D. Is prostacyclin in the major pro-inflammatory prostanoid in joint fluid?. Life Sci 27 (1980) 603-608
196. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90 (1993) 11924-11928
197. Ishihara K., and Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13 (2002) 357-368
198. 2α stimulate differentiation and proliferation, respectively, of clonal osteoblastic MC3T3-E1 cells by different second messengers in vitro. Endocrinology 121 (1987) 1966-1974
199. 2α on the skeleton of osteopenic ovariectomized rats. Bone 17 (1995) 549-554
200. 2α-induced vascular endothelial growth factor synthesis in osteoblasts. Enhancement of MAPK activity. J Biol Chem 278 (2003) 18930-18937
201. Sabbieti M.G., Marchetti L., Gabrielli M.G., Menghi M., Materazzi S., Menghi G., et al. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res 319 (2005) 267-278
202. Harada S., and Thomas K.A. Vascular endothelial growth factors. In: Bilesikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology. 2nd ed. (2002), Academic Press, San Diego 883-902
203. Hurley M.M., Marie P.J., and Florkiewicz R.Z. Fibroblast growth factor (FGF) and FGF receptor families in bone. In: Bilesikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology. 2nd ed. (2002), Academic Press, San Diego 825-852
204. α-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. Mol Endocrinol 17 (2003) 1607-1621
205. 2α on Na-dependent phosphate transport in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 68 (2003) 311-315
206. 2 stimulates calcification of human osteoblastic cells. Biochem Biophys Res Commun 159 (1989) 1206-1212
207. 2+ mobilization in osteoblasts: regulation by protein kinase C. Prostaglandins Leukot Essent Fatty Acids 61 (1999) 189-194
208. 2 on the femoral bone mineral density in ovariectomized rats. Calcif Tissue Int 52 (1993) 442-446
209. 2 by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J Bone Miner Res 20 (2005) 672-681
210. 2 pathway and peroxisome proliferator-activated receptor γ-1 expression are induced by mechanical loading in an osteoblastic cell line. J Periodontal Res 41 (2006) 92-100
211. 1-induced ALP activity in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 70 (2004) 469-474
212. 1 in osteoblasts. J Clin Invest 93 (1994) 2490-2496
213. 1-induced VEGF synthesis in osteoblast-like cells. Mol Cell Endocrinol 220 (2004) 89-95
214. Hamberg M., Svensson J., and Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72 (1975) 2994-2998
215. 2, stimulates bone resorption in vitro and osteoclast-like cell formation in mouse marrow culture. Bone Miner 12 (1991) 15-23
216. 2-stimulated phospholipase D in osteoblast-like cells: possible involvement of PKC. Am J Physiol 269 (1995) E524-E529
217. 4 that mediates chemotaxis. Nature 387 (1997) 620-624
218. 4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192 (2000) 421-432
219. 4: metabolism and signal transduction. Arch Biochem Biophys 385 (2001) 231-241
220. Capra V., Thompson M.D., Sala A., Cole D.E., Folco G., and Rovati G.E. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 27 (2007) 469-527
221. Lynch K.R., O'Neill G.P., Liu Q., Im D.S., Sawyer N., Metters K.M., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 (1999) 789-793
222. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.S., et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275 (2000) 30531-30536
223. Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N., et al. Identification of a novel human eicosanoid receptor coupled to Gi/o. J Biol Chem 277 (2002) 31459-31465
224. Gallwitz W.E., Mundy G.R., Lee C.H., Qiao M., Roodman G.D., Raftery M., et al. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. J Biol Chem 268 (1993) 10087-10094
225. Traianedes K., Dallas M.R., Garrett I.R., Mundy G.R., and Bonewald L.F. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 139 (1998) 3178-3184
226. Meghji S., Sandy J.R., Scutt A.M., Harvey W., and Harris M. Stimulation of bone resorption by lipoxygenase metabolites of arachidonic acid. Prostaglandins 36 (1988) 139-149
227. 4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 11 (1996) 1619-1627
228. 4. Calcif Tissue Int 64 (1999) 154-159
229. Jiang J., Lv H.S., Lin J.H., Jiang D.F., and Chen Z.K. LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. Artif Cells Blood Substit Immobil Biotechnol 33 (2005) 391-403
230. Garcia C., Qiao M., Chen D., Kirchen M., Gallwitz W., Mundy G.R., et al. Effects of synthetic peptido-leukotrienes on bone resorption in vitro. J Bone Miner Res 11 (1996) 521-529
231. 4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 46 (2002) 1804-1812
232. Ren W., and Dziak R. Effects of leukotrienes on osteoblastic cell proliferation. Calcif Tissue Int 49 (1991) 197-201
233. Klickstein L.B., Shapleigh C., and Goetzl E.J. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 66 (1980) 1166-1170
234. 4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis 42 (1983) 677-679
235. 4 and immunological parameters in rheumatoid synovial fluids. Inflammation 15 (1991) 497-503
236. Pelletier J.P., Martel-Pelletier J., and Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 44 (2001) 1237-1247
237. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol 15 (2003) 623-627
238. Baroukh B., and Saffar J.S. The effect of leukotriene synthesis inhibitors on hamster periodontitis. Arch Oral Biol 35 Suppl. (1990) 189S-192S
239. 4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 92 (1995) 517-521
240. 4 receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. Eur J Pharmacol 402 (2000) 275-285
241. 4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis 63 (2004) 170-176
242. 4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 203 (2006) 829-835
243. 4 is required for inflammatory arthritis. J Exp Med 203 (2006) 837-842
244. 4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol 176 (2006) 6254-6261
245. Marcouiller P., Pelletier J.P., Guevremont M., Martel-Pelletier J., Ranger P., Laufer S., et al. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1β synthesis. J Rheumatol 32 (2005) 704-712
246. Wittenberg R.H., Willburger R.E., Kleemeyer K.S., and Peskar B.A. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 36 (1993) 1444-1450
247. Lajeunesse D., Martel-Pelletier J., Fernandes J.C., Laufer S., and Pelletier J.P. Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis. Ann Rheum Dis 63 (2004) 78-83
248. Benveniste J., Henson P.M., and Cochrane C.G. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med 136 (1972) 1356-1377
249. Hanahan D.J. Platelet activating factor: a biologically active phosphoglyceride. Annu Rev Biochem 55 (1986) 483-509
250. Ishii S., and Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 39 (2000) 41-82
251. Honda Z., Ishii S., and Shimizu T. Platelet-activating factor receptor. J Biochem 131 (2002) 773-779
252. Honda Z., Nakamura M., Miki I., Minami M., Watanabe T., Seyama Y., et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 349 (1991) 342-346
253. Ishii S., Kuwaki T., Nagase T., Maki K., Tashiro F., Sunaga S., et al. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 187 (1998) 1779-1788
254. Ishii S., Nagase T., Shindou H., Takizawa H., Ouchi Y., and Shimizu T. Platelet-activating factor receptor develops airway hyperresponsiveness independently of airway inflammation in a murine asthma model. J Immunol 172 (2004) 7095-7102
255. Nagase T., Ishii S., Kume K., Uozumi N., Izumi T., Ouchi Y., et al. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 104 (1999) 1071-1076
256. 2 in bleomycin-induced pulmonary fibrosis. Nat Med 8 (2002) 480-484
257. Souza D.G., Pinho V., Soares A.C., Shimizu T., Ishii S., and Teixeira M.M. Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment. Br J Pharmacol 139 (2003) 733-740
258. Kihara Y., Ishii S., Kita Y., Toda A., Shimada A., and Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med 202 (2005) 853-863
259. Doi K., Okamoto K., Negishi K., Suzuki Y., Nakao A., Fujita T., et al. Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice. Am J Pathol 168 (2006) 1413-1424
260. Soares A.C., Pinho V.S., Souza D.G., Shimizu T., Ishii S., Nicoli J.R., et al. Role of the platelet-activating factor (PAF) receptor during pulmonary infection with gram negative bacteria. Br J Pharmacol 137 (2002) 621-628
261. Talvani A., Santana G., Barcelos L.S., Ishii S., Shimizu T., Romanha A.J., et al. Experimental Trypanosoma cruzi infection in platelet-activating factor receptor-deficient mice. Microbes Infect 5 (2003) 789-796
262. Rijneveld A.W., Weijer S., Florquin S., Speelman P., Shimizu T., Ishii S., et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis 189 (2004) 711-716
263. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11 (1996) 1043-1051
264. Kameda T., Mano H., Yuasa T., Mori Y., Miyazawa K., Shiokawa M., et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186 (1997) 489-495
265. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Clin Invest 106 (2000) 1229-1237
266. Pacifici R., Brown C., Puscheck E., Friedrich E., Slatopolsky E., Maggio D., et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 88 (1991) 5134-5138
267. Ammann P., Rizzoli R., Bonjour J.P., Bourrin S., Meyer J.M., Vassalli P., et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 99 (1997) 1699-1703
268. Kitazawa R., Kimble R.B., Vannice J.L., Kung V.T., and Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94 (1994) 2397-2406
269. Fuller K., Owens J.M., Jagger C.J., Wilson A., Moss R., and Chambers T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med 178 (1993) 1733-1744
270. Suda K., Woo J.T., Takami M., Sexton P.M., and Nagai K. Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-α, IL-1, and RANKL. J Cell Physiol 190 (2002) 101-108
271. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., et al. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 148 (2000) 333-342
272. Lee S.E., Chung W.J., Kwak H.B., Chung C.H., Kwack K.B., Lee Z.H., et al. Tumor necrosis factor-α supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 276 (2001) 49343-49349
273. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4 (1999) 1041-1049
274. Wood D.A., Hapak L.K., Sims S.M., and Dixon S.J. Direct effects of platelet-activating factor on isolated rat osteoclasts. Rapid elevation of intracellular free calcium and transient retraction of pseudopods. J Biol Chem 266 (1991) 15369-15376
275. Zheng Z.G., Wood D.A., Sims S.M., and Dixon S.J. Platelet-activating factor stimulates resorption by rabbit osteoclasts in vitro. Am J Physiol 264 (1993) E74-E81
276. Sato M., Zeng G.Q., and Turner C.H. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 138 (1997) 4330-4337
277. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 119 (2006) S25-S31
278. Kimble R.B., Matayoshi A.B., Vannice J.L., Kung V.T., Williams C., and Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136 (1995) 3054-3061
279. Body J.J. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30 (2002) 75S-79S
280. Noguchi K., Morita I., and Murota S. The detection of platelet-activating factor in inflamed human gingival tissue. Arch Oral Biol 34 (1989) 37-41
281. Pettipher E.R., Higgs G.A., and Henderson B. PAF-acether in chronic arthritis. Agents Actions 21 (1987) 98-103
282. Palacios I., Miguelez R., Sanchez-Pernaute O., Gutierrez S., Egido J., and Herrero-Beaumont G. A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice. J Rheumatol 26 (1999) 1080-1086
283. Sun D., Krishnan A., Zaman K., Lawrence R., Bhattacharya A., and Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res 18 (2003) 1206-1216
284. Calder P.C., and Zurier R.B. Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin Clin Nutr Metab Care 4 (2001) 115-121
285. Smith W.L. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 17 (2005) 174-182
286. Yamamoto S. "Enzymatic" lipid peroxidation: reactions of mammalian lipoxygenases. Free Radic Biol Med 10 (1991) 149-159
287. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25 (2007) 101-137
288. 2 in cultured neonatal mouse calvariae. Endocrinology 135 (1994) 1157-1164
289. 2 synthesis in mouse osteoblasts cultured with interleukin-1. J Biol Chem 272 (1997) 5952-5958
290. Wadleigh D.J., and Herschman H.R. Transcriptional regulation of the cyclooxygenase-2 gene by diverse ligands in murine osteoblasts. Biochem Biophys Res Commun 264 (1999) 865-870
291. Koide M., Murase Y., Yamato K., Noguchi T., Okahashi N., and Nishihara T. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun 259 (1999) 97-102